Market research
VVY.AS Vivoryon Therapeutics N.V
AS EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 6.85
- Dividend yield
- Not available
- Beta
- 1.4
Profile
Instrument facts
- Exchange
- AS
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NL00150002Q7
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 6.85
- Dividend yield
- Not available
- Beta
- 1.4
About
About Vivoryon Therapeutics N.V
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
Research context
Vivoryon Therapeutics N.V appears in PyInvesting’s Amsterdam Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VVY.AS discussion.
5 years, 6 months ago
Vivoryon Therapeutics N.V is currently in a long term uptrend where the price is trading 72.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Vivoryon Therapeutics N.V gets an overall score of 2/5.